

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



European Association of Urology



Guidelines

Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations

C. Wang^{a,*}, E. Nieschlag^b, R. Swerdloff^a, H.M. Behre^c, W.J. Hellstrom^d, L.J. Gooren^e, J.M. Kaufman^f, J.-J. Legros^g, B. Lunenfeld^h, A. Moralesⁱ, J.E. Morley^j, C. Schulman^k, I.M. Thompson^l, W. Weidner^m, F.C.W. Wuⁿ

^a Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles BioMedical Research Institute, Torrance, California, USA

^b Centre for Reproductive Medicine and Andrology, University of Muenster, Muenster, Germany

^c Center for Reproductive Medicine and Andrology, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany

^d Department of Urology, Tulane University, New Orleans, Louisiana, USA

^e Department of Endocrinology, VU University Medical Center, Amsterdam, the Netherlands

^f Department of Endocrinology, Academisch Ziekenhuis, Gent, Belgium

^g Centre Hospitalier Universitaire, Sart-Tilman, Liège, Belgium

^h Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel

ⁱ Centre for Applied Urological Research, Queen's University, Kingston, Canada

^j Division of Geriatric Medicine, St. Louis University, and GRECC, St. Louis VA Medical Center, St. Louis, Missouri, USA

^k Department of Urology, Erasme Hospital, University Clinics Brussels, Brussels, Belgium

^l Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

^m Department of Urology and Pediatric Urology, University Hospitals, Justus-Liebig-University, Giessen, Germany

ⁿ Department of Endocrinology, University of Manchester, Manchester Royal Infirmary, Manchester, United Kingdom

Article info

Article history:

Accepted August 7, 2008

Published online ahead of print on ●●●

* Corresponding author. General Clinical Research Center, Harbor-UCLA Medical Center, 1000 W. Carson St., Torrance, CA 90509, USA.
E-mail address: wang@labiomed.org (C. Wang).

1. Introduction

Demographic data clearly demonstrate that the percent of population in the older age group is increasing. Androgen deficiency in the aging male has become a topic of increasing interest and debate

throughout the world. Cross-sectional and longitudinal data indicate that testosterone falls progressively with age and that a significant percentage of men over the age of 60 yr have serum testosterone levels that are below the lower limits of young adult (age 20–30 yr) men [1–4]. The principal questions

0302-2838/\$ – see back matter © 2008 Published by Elsevier B.V. on behalf of European Association of Urology. doi:10.1016/j.eururo.2008.08.033

raised by these observations are whether older hypogonadal men will benefit from testosterone treatment and what will be the risks associated with such intervention.

The past decade has brought evidence of benefit of androgen treatment of hypogonadal men on multiple target organs, and recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men. This has been comprehensively reviewed and summarized by the Institute of Medicine in “Testosterone and Aging: Clinical Research Directions” [5]. Long-term data on the effects of testosterone treatment in the older population are limited mainly to effects on body composition and bone mass [6–11]. Key questions of the effects of testosterone on patient-reported outcomes and functional benefits that may retard physical or mental frailty of the elderly or improve the quality of life are not yet available. Specific risk data on the prostate and cardiovascular systems are needed.

2. Process for development of recommendations

Recent guidelines for the testosterone treatment of younger hypogonadal men are available from professional societies [12–14]. Recommendations for the diagnosis, treatment, and monitoring of late-onset hypogonadism (LOH) was published by the International Society for the Study of Aging Male (ISSAM) in 2002 [15]. In 2005, a writing committee formed by the International Society of Andrology (ISA), ISSAM, and the European Association of Urology (EAU) prepared a set of recommendations specifically on the “Investigation, Treatment and Monitoring of Late-Onset Hypogonadism.” In order to reach a large audience, these recommendations were published in the *International Journal of Andrology*, the *Journal of Andrology*, *Aging Male*, and *European Urology* [16–19]. In view of the growing interest from practitioners on the treatment of older men with testosterone, the ISA, ISSAM, EAU, European Academy of Andrology (EAA), and American Society of Andrology (ASA) convened meetings of the writing group with expert representatives from each of the societies. The writing group membership from 2005 was expanded to include additional urologists. Members of the writing group met in Berlin, Germany, in 2007; in Toronto, Canada, in 2007; and in Tampa, Florida, in 2008 to revise these recommendations. There was no corporate funding or support for the development of these recommendations. The revised recommendations are

Table 1 – Levels of evidence and grades for revised recommendations

Level	Type of evidence
1a	Evidence obtained from meta-analysis of randomized trials
1b	Evidence obtained from at least one randomized trial
2a	Evidence obtained from one well-designed controlled study without randomization
2b	Evidence obtained from at least one other type of well-designed quasixperimental study
3	Evidence obtained from well-designed nonexperimental studies, such as comparative studies, correlation studies, and case reports
4	Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities
Grade	Nature of recommendations
A	Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomized trial
B	Based on well-conducted clinical studies but without randomized clinical trials
C	Made despite the absence of directly applicable clinical studies of good quality

supported by a selection of appropriate references and categorized by the level of evidence and grade of recommendation according to the US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research (1992) (see Table 1). To ensure broad outreach to multidisciplinary audiences, these recommendations are published in several journals simultaneously.

3. Recommendation 1: Definition

LOH (also referred to as age-associated testosterone deficiency syndrome [TDS]) is a clinical and biochemical syndrome associated with advancing age and characterized by symptoms and a deficiency in serum testosterone levels (below the young healthy adult male reference range) [16–20]. This condition may result in significant detriment to quality of life and adversely affect the function of multiple organ systems.

4. Recommendation 2: Clinical diagnosis and questionnaires

(1) At present, the diagnosis of treatable hypogonadism requires the presence of symptoms and signs suggestive of testosterone deficiency

(level 3, grade A) [12,16–19]. The symptom most associated with hypogonadism is low libido (level 3, grade A) [21,22]. Other manifestations of hypogonadism include erectile dysfunction, decreased muscle mass and strength, increased body fat, decreased bone mineral density and osteoporosis, decreased vitality, and depressed mood. None of these symptoms are specific to the low androgen state but may raise suspicion of testosterone deficiency. One or more of these symptoms must be corroborated with a low serum testosterone level (level 3, grade A) [1,23–25].

- (2) Questionnaires such as Aging Male Symptom Score (AMS) [26,27] and Androgen Deficiency in Aging Men (ADAM) [28] are not recommended for the diagnosis of hypogonadism because of low specificity (level 3, grade B) [24,29,30].

5. Recommendation 3: Laboratory diagnosis

- (1) In patients at risk or who are suspected of hypogonadism, a thorough physical and biochemical work-up is necessary (level 4, grade A). Transient decreases of serum testosterone levels such as those due to acute illnesses should be excluded by careful clinical evaluations and repeated hormone measurement. Hypogonadism (primary or secondary) can occur at all ages, including in elderly men. Risk factors for hypogonadism in older men may include chronic illnesses (including diabetes mellitus, chronic obstructive lung disease, and inflammatory arthritic, renal, and HIV-related diseases), obesity, metabolic syndrome, and hemochromatosis [12]. Such chronic diseases should be investigated and treated (level 4, grade A).
- (2) A serum sample for total testosterone determination should be obtained between 07.00 and 11.00 h (level 2a, grade A) [31]. The most widely accepted parameters to establish the presence of hypogonadism is the measurement of serum total testosterone. There are no generally accepted lower limits of normal. There is, however, general agreement that total testosterone level above 12 nmol/l (350 ng/dl) does not require substitution. Similarly, based on the data of younger men, there is consensus that patients with serum total testosterone levels below 8 nmol/l (230 ng/dl) will usually benefit from testosterone treatment. If the serum total testosterone level is between 8 and 12 nmol/l, repeating the measurement of total testosterone with sex hormone binding globulin (SHBG) to

calculate free testosterone or free testosterone by equilibrium dialysis may be helpful (see 3.5 and 3.7 below) (level 2b, grade A).

- (3) Measurements of serum LH will assist in differentiating between primary and secondary hypogonadism and serum prolactin is indicated when the serum testosterone is lower than 5.2 nmol/l (150 ng/dl) [32–35] or when secondary hypogonadism is suspected [12,36,37] (level 3, grade B).
- (4) Since there are known variations among assay methods, it is imperative that the practitioners utilize reliable laboratories and are acquainted with the reference ranges for testosterone from their local laboratory [38–41] (level 2b, grade A).
- (5) Current immunometric methods for measurement of testosterone can distinguish between hypogonadism and normal adult men; however, methods based on mass spectrometry are more accurate and precise [39–41] (level 2b, grade A) and are increasingly recognized as the method of choice for serum testosterone measurement.
- (6) Measurement of free or bioavailable testosterone should be considered when the serum total testosterone concentration is not diagnostic of hypogonadism, particularly in obese men. There are no generally accepted lower limits of normal for free testosterone for the diagnosis of hypogonadism; however, a free testosterone level below 225 pmol/l (65 pg/ml) can provide supportive evidence for testosterone treatment [37,38,42] (level 3, grade C). Threshold values for bioavailable testosterone depend on the method used and are not generally available [38].
- (7) Equilibrium dialysis is the gold standard for free testosterone measurement. Free testosterone assays based on analog displacement immunoassays are widely available but do not give an accurate measurement of free testosterone; thus, they should not be used [43,44]. Alternately, measuring serum SHBG levels together with a reliable serum total testosterone level provides the data necessary for calculating free testosterone levels (level 2b, grade A). Calculated free testosterone correlates well with free testosterone by equilibrium dialysis [38,42]. Efforts to create standardization of testosterone assays, agreement on standards for testosterone measurement, and accurate reference ranges for testosterone by LC-MS/MS are being developed. International reference standards, characterization of methodology, and population-based reference ranges for free testosterone by equilibrium dialysis are needed. Consensus on the equilibrium constants for testosterone binding

to SHBG and albumin will allow improved calculation of free testosterone [38].

- (8) Salivary testosterone has also been shown to be a reliable substitute for free testosterone measurements but cannot be recommended for general use at this time, since the methodology has not been standardized and adult male ranges are not available in most hospital or reference laboratories [45] (level 3, grade B).
- (9) Alterations in other endocrine systems occur in association with aging (ie, estradiol, GH, and DHEA), but the significance of these changes is not well understood. Determinations of estradiol, thyroid hormones, cortisol, DHEA, DHEA-S, melatonin, GH and IGF-I are not indicated unless other endocrine disorders are suspected based on the clinical signs and symptoms of the patient [12] (level 2, grade A).

6. Recommendation 4: Assessment of treatment outcome and decisions on continued therapy

Improvement in signs and symptoms of testosterone deficiency should be sought.

Failure to benefit from clinical manifestations within a reasonable time interval (3–6 mo is adequate for libido and sexual function, muscle function, and improved body fat; improvement in bone mineral density requires a longer interval to show improvement) should result in discontinuation of treatment. Further investigation for other causes of symptoms is then mandatory (level 1b, grade A).

7. Recommendation 5: Body composition

In men with hypogonadal values of testosterone, testosterone administration improves body composition (decrease of fat mass, increase of lean body mass [5,7,9,10,46] (level 1b, grade A). Secondary benefits of these changes of body composition in strength, muscle function, and metabolic and cardiovascular dysfunction are suggested by available data but require confirmation by large-scale studies.

8. Recommendation 6: Bone density and fracture rate

Osteopenia, osteoporosis, and fracture prevalence rates are greater in hypogonadal younger and older men [47]. Bone density in hypogonadal men of all ages increases under testosterone substitution [8,11,48] (level 1b, grade A). Fracture data are not yet available;

thus, the long-term benefit of testosterone requires further investigation. Assessment of bone density at 2-yr intervals is advisable in hypogonadal men, and serum testosterone measurements should be obtained in all men with osteopenia [49,50].

9. Recommendation 7: Testosterone and sexual function

- (1) The initial assessment of all men with erectile dysfunction and/or diminished libido should include determination of serum testosterone. These dysfunctions, with or without a testosterone deficiency, might be related to comorbidities (ie, diabetes mellitus, hyperprolactinemia, the metabolic syndrome, bladder outlet obstruction, peripheral vascular disease) or medications [51] (level 2a, grade A).
- (2) Men with erectile dysfunction and/or diminished libido and documented testosterone deficiency are candidates for testosterone therapy (level 2a, grade A). An inadequate response to testosterone treatment requires reassessment of the causal mechanisms responsible for the erectile dysfunction (see 7.4 below).
- (3) In the presence of a clinical picture of testosterone deficiency and borderline serum testosterone levels, a short (eg, 3 mo) therapeutic trial may be justified. An absence of response calls for discontinuation of testosterone administration. A satisfactory response might be placebo-generated so that continued assessment is advisable before long-term treatment is recommended [52] (level 2a, grade B).
- (4) There is evidence suggesting therapeutic synergism with combined use of testosterone and phosphodiesterase type 5 inhibitors (PDE5-I) in hypogonadal or borderline eugonadal men [53,54] (level 1b, grade B). These observations are still preliminary and require additional study; however, the combination treatment should be considered in hypogonadal patients with erectile dysfunction (ED) failing to respond to either treatment alone. It is unclear whether men with hypogonadism and ED should be treated initially with PDE5-I, testosterone, or the combination of the two.

10. Recommendation 8: Testosterone and obesity, metabolic syndrome, and type 2 diabetes

- (1) Many of the components of the metabolic syndrome (obesity, hypertension, dyslipidemia,

impaired glucose regulation, and insulin resistance) are also present in hypogonadal men. Numerous epidemiological studies have established a close relationship between obesity and low serum testosterone levels in healthy men [55]. Twenty percent to 64% of obese men have a low serum total or free testosterone level [56]. The metabolic syndrome and type 2 diabetes mellitus are associated with low plasma testosterone [25,55,57-62]. Serum testosterone should be measured in men with type 2 diabetes mellitus with symptoms suggestive of testosterone deficiency (level 2b, grade A).

- (2) The effects of testosterone administration on glycemic control of men with diabetes mellitus are much less certain [63-65]. It is premature to recommend testosterone treatment for the metabolic syndrome or diabetes mellitus in the absence of laboratory and other clinical evidence of hypogonadism. In men with hypogonadism and diabetes and or the metabolic syndrome, testosterone treatment for traditional hypogonadal symptoms may have other unproven benefits for their metabolic status (level 2a, grade B).

11. Recommendation 9: Prostate cancer and benign prostatic hyperplasia

- (1) At the present time, there is no conclusive evidence that testosterone therapy increases the risk of prostate cancer or benign prostatic hyperplasia (BPH) [66,67]. There is also no evidence that testosterone treatment will convert subclinical prostate cancer to clinically detectable prostate cancer (level 4, grade C). There is, however, unequivocal evidence that testosterone can stimulate growth and aggravate symptoms in men with locally advanced and metastatic prostate cancer [68,69] (level 2a, grade A). Currently, adequately powered and optimally designed long-term prostate disease data are not available to determine whether there is any additional risk from testosterone replacement. Hypogonadal older (>45 yr) men should be counseled on the potential risks and benefits of testosterone replacement before treatment and carefully monitored for prostate safety during treatment (level 3, grade A).
- (2) Prior to therapy with testosterone, a man's risk of prostate cancer must be assessed using, as a minimum, digital rectal examination (DRE) and determination of serum prostate-specific antigen (PSA); however, the pretreatment assess-

ment can be improved by incorporating other risk predictors such as age, family history, and ethnicity or race. Several tools have been developed to assist the clinician in assessing prostate cancer risk (eg, online prostate cancer risk calculator) [70,71]. These tools have not been validated for patients with LOH (or TDS). If the patient and physician feel that the risk is sufficiently high, further assessment may be desirable [71,72] (level 2a, grade B); however, pretreatment prostate ultrasound examinations or biopsies are not recommended as routine requirements.

- (3) After initiation of testosterone treatment, patients should be monitored for prostate disease at 3-6 mo, 12 mo, and at least annually thereafter (level 3, grade C). Should the patient's prostate cancer risk be sufficiently high (suspicious finding on DRE, increased PSA, or as calculated using a combination of risk factors noted above), transrectal ultrasound-guided biopsies of the prostate are indicated [73-76] (level 2b, grade A).
- (4) Severe lower urinary tract symptoms (LUTS) evident by a high (>21) International Prostate Symptom Score (IPSS) due to BPH represents a relative contraindication (although there are no compelling data to suggest that testosterone treatment exacerbates LUTS or promotes acute urinary retention) (level 3, grade C). After successful treatment of lower urinary tract obstruction, this contraindication is no longer applicable (level 4, grade C).
- (5) Men successfully treated for prostate cancer and suffering from confirmed symptomatic hypogonadism are potential candidates for testosterone substitution after a prudent interval if there is no clinical or laboratory evidence of residual cancer [77-80]. As long-term outcome data are not available, clinicians must exercise good clinical judgment together with adequate knowledge of advantages and drawbacks of testosterone therapy in this situation [81,82] (level 2b, grade C). The risks and benefits must be clearly discussed with and understood by the patient, and the follow-up must be particularly careful.

12. Recommendation 10: Treatment and delivery systems

- (1) Preparations of natural testosterone should be used for substitution therapy. Currently available intramuscular, subdermal, transdermal, oral, and buccal preparations of testosterone

are safe and effective (level 1b, grade A). The treating physician should have sufficient knowledge and adequate understanding of the pharmacokinetics as well as of the advantages and drawbacks of each preparation. The selection of the preparation should be a joint decision of an informed patient and physician [83].

- (2) Since the possible development of an adverse event during treatment (especially elevated hematocrit or prostate carcinoma) [84] requires rapid discontinuation of testosterone substitution, short-acting preparations may be preferred over long-acting depot preparations in the initial treatment of patients with LOH (level 4, grade C).
- (3) Inadequate data are available to determine the optimal serum testosterone level for efficacy and safety. For the present time, midrange to lower young-adult-male serum testosterone levels seem appropriate as the therapeutic goal [85]. Sustained supraphysiological levels should be avoided. No evidence exists for or against the need to maintain the physiological circadian rhythm of serum testosterone levels (level 3, grade B).
- (4) Obese men are more likely to develop adverse effects [83,85] (level 2b, grade B).
- (5) Preparations of 17- α -alkylated androgen such as 17 α -methyl testosterone are obsolete because of their potential liver toxicity and should no longer be prescribed (level 2b, grade A).
- (6) There is not enough evidence to recommend substitution of dihydrotestosterone (DHT) in aging men; other nontestosterone androgen precursor preparations such as DHEA, DHEA-S, androstenediol, or androstenedione are not recommended (level 1b, grade A).
- (7) Human chorionic gonadotropin (hCG) stimulates testosterone production of Leydig cells, albeit at a lower rate in older men than in younger men. Since insufficient information exists about the therapeutic and adverse effects of hCG treatment in older men and its higher cost, this treatment cannot be recommended in LOH except when fertility is an issue (level 1b, grade B).
- (8) Antiestrogens and aromatase inhibitors have been shown to increase endogenous testosterone levels (level 2b, grade B). Adequate evidence does not exist to recommend their use. Selective androgen receptor modulators (SARMs) are under development but not yet clinically available. Many of these compounds are nonaromatizable, and the risks of long-term use are unclear.

13. Recommendation 11: Adverse effects and monitoring

- (1) Testosterone treatment is contraindicated in men with prostate or breast cancer (level 3, grade A). Testosterone treatment is relatively contraindicated in men at high risk of developing prostate cancer. It is unclear whether localized low-grade (Gleason score <7) prostate cancer represents a relative or absolute contraindication for treatment (see Recommendation 9 for more details) (level 4, grade, C) [83,86,87].
- (2) Men with significant erythrocytosis (hematocrit >52%) (level 3, grade A), untreated obstructive sleep apnea (level 3, grade B), or untreated severe congestive heart failure (level 3, grade B) should not be started on treatment with testosterone without prior resolution of the comorbid condition [83,88].
- (3) Erythrocytosis can develop during testosterone treatment, especially in older men treated by injectable testosterone preparations. Periodic hematological assessment is indicated (ie, before treatment, then at 3–4 mo and at 12 mo in the first year of treatment and annually thereafter). While it is not yet clear what critical threshold is desirable, dose adjustments and/or periodic phlebotomy may be necessary to keep hematocrit below 52–55% [12,82,83] (level 3, grade A).

14. Recommendation 12: Summary

Age is not a contraindication to initiate testosterone treatment. Individual assessment of comorbidities (as possible causes of symptoms) and potential risks versus benefits of testosterone treatment is particularly important in elderly men (level 2a, grade A).

15. Conclusions

The diagnosis of late-onset testosterone deficiency is based on the presence of symptoms or signs and persistently low serum testosterone levels. The benefits and risks of testosterone therapy must be clearly discussed with the patient and assessment of prostate and other risk factors considered before commencing testosterone treatment. Response to testosterone treatment should be assessed. If there is no improvement of symptoms and signs, treatment should be withdrawn and the patient investigated for other possible causes of the clinical presentations.

Conflicts of interest

1 The authors have nothing to disclose.

References

- [1] Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. *J Clin Endocrinol Metab* 2007;92:4241–7.
- [2] Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 1991;73:1016–25.
- [3] Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. *J Clin Endocrinol Metab* 2001;86:724–31.
- [4] Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors. *J Clin Endocrinol Metab* 2008;93:2737–45.
- [5] Liverman CT, Blazer DG. Testosterone and aging: clinical research directions. Washington, DC: National Academies Press; 2004.
- [6] Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. *Clin Endocrinol (Oxf)* 2005;63:381–94.
- [7] Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. *Clin Endocrinol (Oxf)* 2005;63:280–93.
- [8] Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. *J Clin Endocrinol Metab* 2004;89:503–10.
- [9] Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. *J Clin Endocrinol Metab* 2005;90:1502–10.
- [10] Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. *J Clin Endocrinol Metab* 1999;84:2647–53.
- [11] Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. *J Clin Endocrinol Metab* 1999;84:1966–72.
- [12] Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2006;91:1995–2010.
- [13] Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male. *Fertil Steril* 2004;81:1437–40.
- [14] AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. <http://www.aace.com/pub/pdf/guidelines/hypogonadism.pdf>.
- [15] Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. *Aging Male* 2002;5:74–86.
- [16] Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. *Eur Urol* 2005;48:1–4.
- [17] Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. *Aging Male* 2005;8:56–8.
- [18] Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. *Int J Androl* 2005;28:125–7.
- [19] Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. *J Androl* 2006;27:135–7.
- [20] Morales A, Schulman CC, Tostain J, Wu CW. Testosterone deficiency syndrome (TDS) needs to be named appropriately—the importance of accurate terminology. *Eur Urol* 2006;50:407–9.
- [21] Schiavi RC, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. *Psychosom Med* 1991;53:363–74.
- [22] Travison TG, Morley JE, Araujo AB, O'Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. *J Clin Endocrinol Metab* 2006;91:2509–13.
- [23] Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. *J Clin Endocrinol Metab* 2004;89:3813–7.
- [24] Morales A, Spevack M, Emerson L, et al. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. *Aging Male* 2007;10:57–65.
- [25] Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. *J Clin Endocrinol Metab* 2006;91:4335–43.
- [26] Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? *Aging Male* 2004;7:211–8.
- [27] Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. *Eur Urol* 2004;46:80–7.
- [28] Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. *Metabolism* 2000;49:1239–42.
- [29] Tancredi A, Reginster JY, Schleich F, et al. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. *Eur J Endocrinol* 2004;151:355–60.

- [30] Beutel ME, Wiltink J, Hauck EW, et al. Correlations between hormones, physical, and affective parameters in aging urologic outpatients. *Eur Urol* 2005;47:749–55. 752
- [31] Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. *Clin Endocrinol (Oxf)* 2003;58:710–7. 753
- [32] Citron JT, Ettinger B, Rubinoff H, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. *J Urol* 1996;155:529–33. 754
- [33] Bunch TJ, Abraham D, Wang S, Meikle AW. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. *Aging Male* 2002;5:38–46. 755
- [34] Rhoden EL, Estrada C, Levine L, Morgentaler A. The value of pituitary magnetic resonance imaging in men with hypogonadism. *J Urol* 2003;170:795–8. 756
- [35] Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. *J Urol* 1997;158:1764–7. 757
- [36] Araujo AB, O'Donnell A, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. *J Clin Endocrinol Metab* 2004;89:5920–6. 758
- [37] Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. *J Endocrinol Invest* 2005;28:28–31. 759
- [38] Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. *J Clin Endocrinol Metab* 2007;92:405–13. 760
- [39] Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA, Handelsman DJ. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. *J Clin Endocrinol Metab* 2005;90:5928–36. 761
- [40] Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. *Clin Chem* 2003;49:1381–95. 762
- [41] Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. *J Clin Endocrinol Metab* 2004;89:534–43. 763
- [42] Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666–72. 764
- [43] Swerdloff RS, Wang C. Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence. *Clin Chem* 2008;54:458–60. 765
- [44] Rosner W. Errors in the measurement of plasma free testosterone. *J Clin Endocrinol Metab* 1997;82:2014–5. 766
- [45] Wang C, Plymate S, Nieschlag E, Paulsen CA. Salivary testosterone in men: further evidence of a direct correlation with free serum testosterone. *J Clin Endocrinol Metab* 1981;53:1021–4. 767
- [46] Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. *J Clin Endocrinol Metab* 2008;93:139–46. 768
- [47] Meier C, Nguyen TV, Handelsman DJ, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. *Arch Intern Med* 2008;168:47–54. 769
- [48] Kenny AM, Prestwood KM, Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. *Endocr Res* 2000;26:153–68. 770
- [49] Freitas SS, Barrett-Connor E, Ensrud KE, et al. Rate and circumstances of clinical vertebral fractures in older men. *Osteoporos Int* 2008;19:615–23. 771
- [50] Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. *JAMA* 2007;298:629–37. 772
- [51] Morales A, Buvat J, Gooren LJ, et al. Endocrine aspects of sexual dysfunction in men. *J Sex Med* 2004;1:69–81. 773
- [52] Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: Can a case be made for a 3-month therapeutic trial? *BJU Int* 2004;94:1066–70. 774
- [53] Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. *J Urol* 2004;172:658–63. 775
- [54] Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? *J Urol* 2005;173:530–2. 776
- [55] Allen NE, Appleby PN, Davey GK, Key TJ. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. *Cancer Causes Control* 2002;13:353–63. 777
- [56] Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. *Curr Opin Endocrinol Diabetes Obes* 2007;14:226–34. 778
- [57] Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). *Diabetes Care* 2007;30:234–8. 779
- [58] Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. *J Clin Endocrinol Metab* 2007;92:3568–72. 780
- [59] Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. *Clin Endocrinol (Oxf)* 2006;65:125–31. 781
- [60] Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. *Diabetes Care* 2007;30:911–7. 782
- [61] Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total 783

- 811 testosterone, and symptomatic androgen deficiency are
812 associated with development of the metabolic syndrome
813 in nonobese men. *J Clin Endocrinol Metab* 2006;91:843-50.
814 [62] Laaksonen DE, Niskanen L, Punnonen K, et al. Testoster-
815 one and sex hormone-binding globulin predict the meta-
816 bolic syndrome and diabetes in middle-aged men.
817 *Diabetes Care* 2004;27:1036-41.
818 [63] Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone
819 replacement therapy improves insulin resistance, glycae-
820 mic control, visceral adiposity and hypercholesterolaemia
821 in hypogonadal men with type 2 diabetes. *Eur J*
822 *Endocrinol* 2006;154:899-906.
823 [64] Corrales JJ, Burgo RM, Garca-Berrocal B, et al. Partial
824 androgen deficiency in aging type 2 diabetic men and
825 its relationship to glycemic control. *Metabolism* 2004;
826 53:666-72.
827 [65] Basu R, Dalla MC, Campioni M, et al. Effect of 2 years of
828 testosterone replacement on insulin secretion, insulin
829 action, glucose effectiveness, hepatic insulin clearance,
830 and postprandial glucose turnover in elderly men. *Dia-*
831 *betes Care* 2007;30:1972-8.
832 [66] Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex
833 hormones and prostate cancer: a collaborative analysis of
834 18 prospective studies. *J Natl Cancer Inst* 2008;100:170-83.
835 [67] Carpenter WR, Robinson WR, Godley PA. Getting over
836 testosterone: postulating a fresh start for etiologic studies
837 of prostate cancer. *J Natl Cancer Inst* 2008;100:158-9.
838 [68] Fowler Jr JE, Whitmore Jr WF. Considerations for the use
839 of testosterone with systemic chemotherapy in prostatic
840 cancer. *Cancer* 1982;49:1373-7.
841 [69] McConnell JD. Prostatic growth: new insights into hormonal
842 regulation. *Br J Urol* 1995;76(Suppl 1):5-10.
843 [70] Parekh DJ, Ankerst DP, Higgins BA, et al. External valida-
844 tion of the Prostate Cancer Prevention Trial risk calculator
845 in a screened population. *Urology* 2006;68:1152-5.
846 [71] Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate
847 cancer risk: results from the Prostate Cancer Prevention
848 Trial. *J Natl Cancer Inst* 2006;98:529-34.
849 [72] Thompson IM, Carroll PR, Carducci MA. Recommenda-
850 tions for defining and treating high risk localized prostate
851 cancer. *J Urol* 2006;176:S6-10.
852 [73] Marks LS, Mazer NA, Mostaghel E, et al. Effect of testos-
853 terone replacement therapy on prostate tissue in men
854 with late-onset hypogonadism: a randomized controlled
855 trial. *JAMA* 2006;296:2351-61.
856 [74] Meikle AW, Arver S, Dobs AS, et al. Prostate size in
857 hypogonadal men treated with a nonscrotal permeation-
858 enhanced testosterone transdermal system. *Urology*
859 1997;49:191-6.
860 [75] Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham
861 GR. Managing the risks of prostate disease during testos-
862 terone replacement therapy in older men: recommenda-
863 tions for a standardized monitoring plan. *J Androl*
864 2003;24:299-311.
865 [76] Rhoden EL, Morgentaler A. Risks of testosterone-replace-
866 ment therapy and recommendations for monitoring.
867 *N Engl J Med* 2004;350:482-92.
868 [77] Agarwal PK, Oefelein MG. Testosterone replacement ther-
869 apy after primary treatment for prostate cancer. *J Urol*
870 2005;173:533-6.
871 [78] Kaufman JM, Graydon RJ. Androgen replacement after
872 curative radical prostatectomy for prostate cancer in
873 hypogonadal men. *J Urol* 2004;172:920-2.
874 [79] Khera M, Lipshultz LI. The role of testosterone replace-
875 ment therapy following radical prostatectomy. *Urol Clin*
876 *North Am* 2007;34:549-53, vi.
877 [80] Sarosdy MF. Testosterone replacement for hypogonadism
878 after treatment of early prostate cancer with brachyther-
879 apy. *Cancer* 2007;109:536-41.
880 [81] Nieschlag E, Behre HM. Testosterone: action, deficiency,
881 substitution. 3rd ed. Cambridge, UK: Cambridge Univer-
882 sity Press; 2004.
883 [82] Nieschlag E. Testosterone treatment comes of age: new
884 options for hypogonadal men. *Clin Endocrinol (Oxf)* 2006;
885 65:275-81.
886 [83] Calof OM, Singh AB, Lee ML, et al. Adverse events asso-
887 ciated with testosterone replacement in middle-aged and
888 older men: a meta-analysis of randomized, placebo-con-
889 trolled trials. *J Gerontol A Biol Sci Med Sci* 2005;60:1451-7.
890 [84] Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter
891 EJ. Serum testosterone and the risk of prostate cancer:
892 potential implications for testosterone therapy. *Cancer*
893 *Epidemiol Biomarkers Prev* 2005;14:2257-60.
894 [85] Zitzmann M, Nieschlag E. Androgen receptor gene CAG
895 repeat length and body mass index modulate the safety of
896 long-term intramuscular testosterone undecanoate ther-
897 apy in hypogonadal men. *J Clin Endocrinol Metab* 2007;
898 92:3844-53.
899 [86] Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH,
900 Channer KS. Testosterone therapy in men with moderate
901 severity heart failure: a double-blind randomized placebo
902 controlled trial. *Eur Heart J* 2006;27:57-64.
903 [87] Hanafy HM. Testosterone therapy and obstructive sleep
904 apnea: Is there a real connection? *J Sex Med* 2007;4:1241-6.
905 [88] Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I,
906 Rudman D. Polycythemia as a complication of testos-
907 terone replacement therapy in nursing home men with low
908 testosterone levels. *J Am Geriatr Soc* 1995;43:899-901.
909
910
911